^
CANCER:

Neuroendocrine Tumor

No biomarker
Neuroendocrine Tumor
surufatinib
Sensitive: A1 - Approval
No biomarker
Neuroendocrine Tumor
sunitinib
Sensitive: A1 - Approval
No biomarker
Neuroendocrine Tumor
everolimus
Sensitive: A1 - Approval
No biomarker
Neuroendocrine Tumor
lanreotide prolonged-release subcutaneous
Sensitive: A1 - Approval
No biomarker
Neuroendocrine Tumor
sunitinib
Sensitive: A1 - Approval
VHL mutation
Neuroendocrine Tumor
belzutifan
Sensitive: A1 - Approval
No biomarker
Neuroendocrine Tumor
EP
Sensitive: A2 - Guideline
No biomarker
Neuroendocrine Tumor
octreotide
Sensitive: A2 - Guideline
No biomarker
Neuroendocrine Tumor
temozolomide
Sensitive: A2 - Guideline
SSTR positive
Neuroendocrine Tumor
lanreotide prolonged-release subcutaneous
Sensitive: A2 - Guideline
SSTR positive
Neuroendocrine Tumor
octreotide
Sensitive: A2 - Guideline
No biomarker
Neuroendocrine Tumor
FOLFOX
Sensitive: A2 - Guideline
No biomarker
Neuroendocrine Tumor
carboplatin + etoposide IV
Sensitive: A2 - Guideline
No biomarker
Neuroendocrine Tumor
temozolomide + capecitabine
Sensitive: A2 - Guideline
MSI-H/dMMR
Neuroendocrine Tumor
pembrolizumab
Sensitive: A2 - Guideline
No biomarker
Neuroendocrine Tumor
oxaliplatin
Sensitive: A2 - Guideline
No biomarker
Neuroendocrine Tumor
dacarbazine
Sensitive: A2 - Guideline
No biomarker
Neuroendocrine Tumor
cisplatin + etoposide IV
Sensitive: A2 - Guideline
No biomarker
Neuroendocrine Tumor
5-fluorouracil
Sensitive: A2 - Guideline
No biomarker
Neuroendocrine Tumor
capecitabine
Sensitive: A2 - Guideline
No biomarker
Neuroendocrine Tumor
nivolumab + ipilimumab
Sensitive: A2 - Guideline
No biomarker
Neuroendocrine Tumor
pembrolizumab
Sensitive: A2 - Guideline
No biomarker
Neuroendocrine Tumor
FOLFIRINOX
Sensitive: A2 - Guideline
No biomarker
Neuroendocrine Tumor
carboplatin + irinotecan
Sensitive: A2 - Guideline
No biomarker
Neuroendocrine Tumor
cisplatin + irinotecan
Sensitive: A2 - Guideline
No biomarker
Neuroendocrine Tumor
FOLFIRI
Sensitive: A2 - Guideline
No biomarker
Neuroendocrine Tumor
CAPOX
Sensitive: A2 - Guideline
No biomarker
Neuroendocrine Tumor
5-fluorouracil + streptozocin
Sensitive: A2 - Guideline
No biomarker
Neuroendocrine Tumor
doxorubicin hydrochloride + streptozocin
Sensitive: A2 - Guideline
No biomarker
Neuroendocrine Tumor
streptozocin
Sensitive: A2 - Guideline
TMB-H
Neuroendocrine Tumor
pembrolizumab
Sensitive: A2 - Guideline
No biomarker
Neuroendocrine Tumor
FAS
Sensitive: A2 - Guideline
No biomarker
Neuroendocrine Tumor
carboplatin + cabazitaxel
Sensitive: A2 - Guideline
SSTR positive
Neuroendocrine Tumor
lutetium Lu 177 dotatate
Sensitive: B - Late Trials
BRAF V600E
Neuroendocrine Tumor
trametinib + dabrafenib
Sensitive: C1 - Off-label
RET fusion
Neuroendocrine Tumor
selpercatinib
Sensitive: C1 - Off-label
DLL3 overexpression
Neuroendocrine Tumor
rovalpituzumab tesirine
Sensitive: C2 – Inclusion Criteria
SSTR2 positive
Neuroendocrine Tumor
PEN-221
Sensitive: C2 – Inclusion Criteria
PD-L1 expression
Neuroendocrine Tumor
toripalimab
Sensitive: C2 – Inclusion Criteria
PD-L1 expression
Neuroendocrine Tumor
PDR001
Sensitive: C3 – Early Trials
mTOR expression + RPS6KB1 expression
Neuroendocrine Tumor
everolimus
Sensitive: C3 – Early Trials
MGMT deletion
Neuroendocrine Tumor
temozolomide
Sensitive: C3 – Early Trials
TMB-H
Neuroendocrine Tumor
toripalimab
Sensitive: C3 – Early Trials
FGFR4 G388R
Neuroendocrine Tumor
everolimus
Resistant: C3 – Early Trials
CA9 overexpression
Neuroendocrine Tumor
doxorubicin hydrochloride
Resistant: C3 – Early Trials
FLT4 T494A
Neuroendocrine Tumor
pazopanib
Resistant: C3 – Early Trials
FLT4 R1324L
Neuroendocrine Tumor
pazopanib
Resistant: C3 – Early Trials
VHL mutation
Neuroendocrine Tumor
PT2385
Sensitive: C3 – Early Trials
TP53 mutation
Neuroendocrine Tumor
pazopanib
Sensitive: C3 – Early Trials
SSTR5 expression
Neuroendocrine Tumor
octreotide
Sensitive: C3 – Early Trials
SSTR2 expression
Neuroendocrine Tumor
octreotide
Sensitive: C3 – Early Trials
SSTR Expression
Neuroendocrine Tumor
ORM-2110
Sensitive: C3 – Early Trials
MSI-H/dMMR + PD-L1 expression
Neuroendocrine Tumor
Immunotherapy
Sensitive: C3 – Early Trials
ARID1A mutation
Neuroendocrine Tumor
toripalimab
Sensitive: C3 – Early Trials
TMB-L
Neuroendocrine Tumor
toripalimab
Sensitive: C3 – Early Trials
TGFB1-H
Neuroendocrine Tumor
everolimus
Resistant: C3 – Early Trials
PD-L1-H
Neuroendocrine Tumor
everolimus
Resistant: C3 – Early Trials
EWSR1-CREB1 fusion
Neuroendocrine Tumor
crizotinib + pazopanib
Sensitive: C4 – Case Studies
MUC16 elevation
Neuroendocrine Tumor
TC
Sensitive: C4 – Case Studies
TMB-L + PD-L1 expression
Neuroendocrine Tumor
nivolumab + ipilimumab
Sensitive: C4 – Case Studies
BRAF V600E
Neuroendocrine Tumor
pazopanib
Resistant: C4 – Case Studies
BRAF V600E
Neuroendocrine Tumor
trametinib + vemurafenib
Sensitive: C4 – Case Studies
BRCA2 exon 11 deletion
Neuroendocrine Tumor
olaparib
Resistant: C4 – Case Studies
ETV6-NTRK3 fusion
Neuroendocrine Tumor
entrectinib
Sensitive: C4 – Case Studies
CEACAM5 expression
Neuroendocrine Tumor
IMMU-130
Sensitive: D – Preclinical
TYRO3 mutation + ALK mutation
Neuroendocrine Tumor
sunitinib
Sensitive: D – Preclinical
TYRO3 mutation + ALK mutation
Neuroendocrine Tumor
crizotinib + sunitinib
Sensitive: D – Preclinical
TYRO3 mutation + ALK mutation
Neuroendocrine Tumor
crizotinib
Resistant: D – Preclinical